The increasing interest in potent weight management has led to considerable investigation into novel treatments. Recently , Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activator , has demonstrated promising results in patient trials, suggesting potential for substantial